NIKKEI 225
33,480.66 -6.23 (-0.02%) HANG SENG
16,926.30 -116.58 (-0.68%) CRUDE OIL
75.74 -0.22 (-0.29%) GOLD FUTURES
2,061.50 +4.30 (+0.21%) DOW
35,950.89 +520.47 (+1.47%) Bitcoin GBP
29,941.95 +84.32 (+0.28%)
Photocure ASA (0IMT.L)
| Previous close | 50.20 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 7,089 |
| Market cap | 9.729M |
| Beta (5Y monthly) | 0.79 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.53 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China. Hexvix, a pharmaceutical product used in the detection of bladder cancer, was licensed to Asieris by Photocure in January 2021, for the registration and commercialization of Hexvix in mainland China and Taiwan.
- PR Newswire
Photocure to present at four investor conferences in November/December 2023
Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces its participation in four investor conferences focusing on the healthcare sector in Q4 2023:
PR NewswirePhotocure ASA: Results for the third quarter of 2023
Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 107.3 million in the third quarter of 2023 (Q3 2022: NOK 96.9 million), and an EBITDA of NOK 3.3 million (NOK 4.7 million) for the company. Photocure refines its guidance ranges for 2023: The Company continues to expect 65-75 new Saphira™ blue light tower installations assuming delivery of an anticipated large purchase order in Q4; consolidated product revenue growth in the range of 17-20% including the impact of FX and the
